Cinzia Baldessari, Fabio Gelsomino, Andrea Spallanzani, Giuseppe Pugliese, Luca Reggiani Bonetti, Stefania Bettelli, Stefano Cascinu
{"title":"Beyond the Beyond: A Case of an Extraordinary Response to Multiple Lines of Therapy in a de novo Metastatic HER2-Negative Gastric Cancer Patient.","authors":"Cinzia Baldessari, Fabio Gelsomino, Andrea Spallanzani, Giuseppe Pugliese, Luca Reggiani Bonetti, Stefania Bettelli, Stefano Cascinu","doi":"10.1159/000488983","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer is the fourth cause of cancer-related death in Europe and the prognosis of these patients remains dismal. It has been demonstrated that chemotherapy improved survival compared with best supportive care and recently, subsequent lines of therapy, also with new drugs, obtained positive results.</p><p><strong>Summary: </strong>We present the case of a patient diagnosed with a de novo metastatic gastric cancer who experienced an extraordinary long response to multiple lines of chemotherapy (FOLFOX6, paclitaxel plus ramucirumab, FOLFIRI, rechallenge with FOLFOX6).</p><p><strong>Key message: </strong>Gastric cancer therapy should be considered as the result of a strategy based on the patient's condition, and tolerance and response to various therapies. The emerging evidence of the role of subsequent lines of therapy, along with the recognition of the pivotal role of nutritional support and the availability of new drugs, should help clinicians in the management of patients with gastric cancer.</p><p><strong>Practical implications: </strong>We propose a practical therapeutic algorithm in order to help clinicians who deal with patients with gastric cancer.</p>","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"5 1-2","pages":"14-20"},"PeriodicalIF":0.8000,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000488983","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastrointestinal Tumors","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000488983","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/7/27 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 4
Abstract
Background: Gastric cancer is the fourth cause of cancer-related death in Europe and the prognosis of these patients remains dismal. It has been demonstrated that chemotherapy improved survival compared with best supportive care and recently, subsequent lines of therapy, also with new drugs, obtained positive results.
Summary: We present the case of a patient diagnosed with a de novo metastatic gastric cancer who experienced an extraordinary long response to multiple lines of chemotherapy (FOLFOX6, paclitaxel plus ramucirumab, FOLFIRI, rechallenge with FOLFOX6).
Key message: Gastric cancer therapy should be considered as the result of a strategy based on the patient's condition, and tolerance and response to various therapies. The emerging evidence of the role of subsequent lines of therapy, along with the recognition of the pivotal role of nutritional support and the availability of new drugs, should help clinicians in the management of patients with gastric cancer.
Practical implications: We propose a practical therapeutic algorithm in order to help clinicians who deal with patients with gastric cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
